Thermo Fisher Scientific Quarterly Balance Sheet
NYSE: TMOIndustrialsIndustrial Machinery/ComponentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Thermo Fisher Scientific financial position
As of Jun 27, 2026, Thermo Fisher Scientific reported total assets of $113.17 billion, up 11.8% from a year earlier against total liabilities of $60.49 billion. Shareholders' equity stood at $52.68 billion, or 46.5% of assets. The company held $4.06 billion in cash and equivalents against $42.55 billion of debt, a net debt position of $38.48 billion.
The current ratio (current assets divided by current liabilities) was 1.55, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.81.
Summary generated from market data by MetaCap's automated system. Methodology
Thermo Fisher Scientific balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-27 | Q1 20262026-03-28 | Q4 20252025-12-31 | Q3 20252025-09-27 | Q2 20252025-06-28 | Q1 20252025-03-29 | Q4 20242024-12-31 | Q3 20242024-09-28 | Q2 20242024-06-29 | Q1 20242024-03-30 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 4.06B | 3.25B | 9.85B | 1.98B | 4.58B | 4.13B | 4.01B | 4.64B | 7.07B | 5.50B | 8.08B | 6.15B |
| Short-Term Investments | 0 | 2.00M | 253.00M | 1.56B | 1.81B | 1.81B | 1.56B | 2.00B | 1.75B | 1.75B | 3.00M | — |
| Receivables | 9.45B | 9.20B | 8.90B | 8.91B | 8.59B | 8.46B | 8.19B | 8.26B | 7.94B | 7.93B | 8.22B | 8.37B |
| Inventory | 5.63B | 5.50B | 5.42B | 5.75B | 5.56B | 5.22B | 4.98B | 5.43B | 5.20B | 5.13B | 5.09B | 5.40B |
| Total Current Assets | 23.36B | 22.32B | 28.71B | 22.30B | 24.58B | 23.38B | 22.14B | 23.78B | 25.48B | 23.64B | 24.59B | 23.09B |
| Property, Plant & Equipment | 10.76B | 10.66B | 10.56B | 10.18B | 9.63B | 9.33B | 9.31B | 9.41B | 9.28B | 9.32B | 9.45B | 9.17B |
| Goodwill | 54.83B | 55.19B | 49.36B | 49.29B | 47.25B | 46.49B | 45.85B | 46.73B | 43.84B | 43.84B | 44.02B | 43.58B |
| Intangible Assets | 18.61B | 19.15B | 15.84B | 16.24B | 15.15B | 15.32B | 15.53B | 16.26B | 15.52B | 16.05B | 16.67B | 17.09B |
| Total Assets | 113.17B | 113.28B | 110.34B | 103.02B | 101.23B | 99.04B | 97.32B | 100.36B | 98.50B | 97.09B | 98.73B | 97.06B |
| Accounts Payable | 3.27B | 3.34B | 3.62B | 3.12B | 2.98B | 3.05B | 3.08B | 2.61B | 2.55B | 2.56B | 2.87B | 2.51B |
| Short-Term Debt | 3.37B | 3.09B | 3.53B | 3.82B | 2.21B | 2.82B | 2.21B | 4.12B | 5.12B | 4.45B | 3.61B | 4.79B |
| Total Current Liabilities | 15.07B | 14.62B | 15.19B | 14.89B | 12.72B | 13.17B | 13.33B | 14.60B | 14.77B | 13.94B | 14.01B | 14.16B |
| Long-Term Debt | 39.18B | 40.07B | 35.85B | 31.86B | 33.02B | 31.37B | 29.06B | 31.20B | 30.28B | 31.16B | 31.31B | 30.49B |
| Total Liabilities | 60.49B | 61.34B | 56.93B | 52.00B | 50.75B | 49.68B | 47.77B | 51.39B | 51.08B | 51.59B | 52.00B | 51.71B |
| Shareholders' Equity | 52.68B | 51.93B | 53.41B | 51.02B | 50.51B | 49.39B | 49.58B | 48.99B | 47.43B | 45.52B | 46.73B | 45.33B |
| Retained Earnings | 62.19B | 60.63B | 59.16B | 57.35B | 55.90B | 54.45B | 53.10B | 51.42B | 49.94B | 48.54B | 47.36B | 45.87B |
| Total Debt | 42.55B | 43.16B | 39.38B | 35.68B | 35.23B | 34.19B | 31.27B | 35.31B | 35.41B | 35.61B | 34.92B | 35.28B |
| Net Cash (Debt) | -38.48B | -39.91B | -29.28B | -32.13B | -28.84B | -28.24B | -25.70B | -28.67B | -26.58B | -28.36B | -26.84B | -29.13B |
This table shows 12 quarterly periods of Thermo Fisher Scientific's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TMO's reporting calendar. What is a balance sheet?